Cargando…
Rac inhibition as a novel therapeutic strategy for EGFR/HER2 targeted therapy resistant breast cancer
BACKGROUND: Even though targeted therapies are available for cancers expressing oncogenic epidermal growth receptor (EGFR) and (or) human EGFR2 (HER2), acquired or intrinsic resistance often confounds therapy success. Common mechanisms of therapy resistance involve activating receptor point mutation...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170972/ https://www.ncbi.nlm.nih.gov/pubmed/34074257 http://dx.doi.org/10.1186/s12885-021-08366-7 |